Hrher2 | List of Frontiers open access articles

Review

Published on 24 Jan 2024

Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy

in Experimental Pharmacology and Drug Discovery

Lu-Qi Cao
Haidong Sun
Yuhao Xie
Harsh Patel
Letao Bo
Hanli Lin
Zhe-Sheng Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1340764

18,711 views
40 citations

Original Research

Published on 05 Aug 2021

Candidates of Genomic Tests in HR+/HER2- Breast Cancer Patients With 1-2 Positive Sentinel Lymph Node Without Axillary Lymph Node Dissection: Analysis From Multicentric Cohorts

in Breast Cancer

Zhao Bi
Jia-Jian Chen
Peng-Chen Liu
Peng Chen
Wei-Li Wang
Yan-Bing Liu
Chun-Jian Wang
Peng-Fei Qiu
Qing Lv
Jiong Wu

Frontiers in Oncology

doi 10.3389/fonc.2021.722325

5,432 views
7 citations

PDF-read only

Review

Published on 29 Jul 2019

CDK4/6 inhibitors in advanced breast cancer, what is beyond?

Amrallah A. Mohammed
Hanaa Rashied
Fifi Mostafa Elsayed

Oncology Reviews

doi 10.4081/oncol.2019.416

Original Research

Published on 24 Sep 2021

Miller–Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy

in Breast Cancer

Liye Wang
Rongzhen Luo
Qianyi Lu
Kuikui Jiang
Ruoxi Hong
Kaping Lee
Ping Zhang
Danyang Zhou
Shusen Wang
Fei Xu

Frontiers in Oncology

doi 10.3389/fonc.2021.735670

10,347 views
18 citations

Original Research

Published on 08 Jun 2023

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients

in Breast Cancer

Jinhao Wang
Yaxin Liu
Yuehua Liang
Yue Zhang
Hang Dong
Tiantian Zheng
Jianjun Yu
Pan Du
Shidong Jia
Bonnie L. King

Frontiers in Oncology

doi 10.3389/fonc.2023.1152575

6,990 views
5 citations

Original Research

Published on 11 Aug 2023

Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer

in Breast Cancer

Sarah Sammons
Andrew Elliott
Romualdo Barroso-Sousa
Saranya Chumsri
Antoinette R. Tan
George W. Sledge
Sara M. Tolaney
Evanthia T. Roussos Torres

Frontiers in Oncology

doi 10.3389/fonc.2023.1235902

6,563 views
11 citations

Original Research

Published on 03 Mar 2022

Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China

in Breast Cancer

Zhanhong Chen
Quchang Ouyang
Yongsheng Wang
Junsheng Wang
Haixue Wang
Xiaohong Wu
Peili Zhang
Jian Huang
Yabing Zheng
Wenming Cao

Frontiers in Oncology

doi 10.3389/fonc.2022.829693

7,054 views
9 citations

Case Report

Published on 08 May 2026

Sequential CDK4/6 inhibition in bone-only metastatic HR+/HER2- breast cancer: a case of prolonged disease control with abemaciclib after clinical progression on palbociclib-based therapy

in Translational Medicine

Xuejiao Peng
Weiqin Chang

Frontiers in Medicine

doi 10.3389/fmed.2026.1775724

337 views

Original Research

Published on 01 Jul 2022

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population

in Breast Cancer

Yimin Zhu
Jiayu Wang
Binghe Xu

Frontiers in Oncology

doi 10.3389/fonc.2022.918759

2,935 views
4 citations

Systematic Review

Published on 02 May 2023

Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer

in Breast Cancer

Anagha Gogate
Sandip Ranjan
Amit Kumar
Hitesh Bhandari
Eros Papademetriou
Inkyu Kim
Ravi Potluri

Frontiers in Oncology

doi 10.3389/fonc.2023.1119102

5,340 views
2 citations

Original Research

Published on 30 Jul 2025

Using baseline MRI radiomics to predict the tumor shrinkage patterns in HR-Positive, HER2-Negative Breast Cancer

in Breast Cancer

Lijia Wang
Yongchen Wang
Li Yang
Jialiang Ren
Qian Xu
Yingmin Zhai
Tao Zhou

Frontiers in Oncology

doi 10.3389/fonc.2025.1539644

2,237 views
1 citation

Original Research

Published on 17 Jun 2025

Abemaciclib treatment patterns and outcome in HR+/HER2- locally advanced or metastatic breast cancer: a real-world study from Kuwait and Lebanon

in Breast Cancer

Anwar Al Nouri
Faisal Al Terkait
Nagi El Saghir
Hady Ghanem
Joseph Kattan
Cynthia Bishouti
Jade Dreyer
Soniya Rai
Alexandru Rosca

Frontiers in Oncology

doi 10.3389/fonc.2025.1437380

3,749 views

Original Research

Published on 23 Feb 2021

Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2− Early Breast Cancer

in Women's Cancer

Mi Jeong Kwon
Jai Min Ryu
Soo Youn Cho
Seok Jin Nam
Seok Won Kim
Jeeyeon Lee
Soo Jung Lee
Ji-Young Park
Ho Yong Park
Sungjun Hong

Frontiers in Oncology

doi 10.3389/fonc.2021.588728

12,278 views
4 citations

Original Research

Published on 26 Nov 2025

Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial

in Drugs Outcomes Research and Policies

Xiaohu Jin
Zhifeng Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1700291

1,342 views

Original Research

Published on 09 Sep 2022

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach

in Breast Cancer

Alessandra Fabi
Giuseppe Buono
Emilio Bria
Giampaolo Bianchini
Giuseppe Curigliano
Michelino De Laurentiis
Sabino De Placido
Lucia Del Mastro
Valentina Guarneri
Daniele Generali

Frontiers in Oncology

doi 10.3389/fonc.2022.950861

4,530 views
1 citation

Review

Published on 13 Mar 2026

Therapeutic advances in HR+/HER2- advanced breast cancer after failure of CDK4/6 inhibitor therapy

in Breast Cancer

Mengqi Cui
Junjuan Xiao
Lin Ma
Yue Liang
Jing Liang

Frontiers in Oncology

doi 10.3389/fonc.2026.1763278

759 views

Articles

Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy

Candidates of Genomic Tests in HR+/HER2- Breast Cancer Patients With 1-2 Positive Sentinel Lymph Node Without Axillary Lymph Node Dissection: Analysis From Multicentric Cohorts

CDK4/6 inhibitors in advanced breast cancer, what is beyond?

Miller–Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients

Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer

Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China

Sequential CDK4/6 inhibition in bone-only metastatic HR+/HER2- breast cancer: a case of prolonged disease control with abemaciclib after clinical progression on palbociclib-based therapy

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population

Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer

Using baseline MRI radiomics to predict the tumor shrinkage patterns in HR-Positive, HER2-Negative Breast Cancer

Abemaciclib treatment patterns and outcome in HR+/HER2- locally advanced or metastatic breast cancer: a real-world study from Kuwait and Lebanon

Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2− Early Breast Cancer

Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach

Therapeutic advances in HR+/HER2- advanced breast cancer after failure of CDK4/6 inhibitor therapy